Dettbarn C A, Betto R, Salviati G, Palade P, Jenkins G M, Sabbadini R A
University of Texas Medical Branch at Galveston 77550.
J Mol Cell Cardiol. 1994 Feb;26(2):229-42. doi: 10.1006/jmcc.1994.1026.
Excitation contraction (EC) coupling in muscle cells involves the movement of calcium through the calcium release channel of the sarcoplasmic reticulum (SR) membrane known as the ryanodine receptor. We have recently shown that the novel second messenger, sphingosine, can block calcium release from skinned skeletal muscle fibers and from isolated skeletal muscle SR membranes (Sabbadini et al., J Biol Chem 267: 15475-15484, 1992). In this report, we demonstrate that sphingosine also inhibits calcium release from isolated canine cardiac SR membranes containing the ryanodine receptor when release is induced by caffeine, doxorubicin or by calcium. Sphingosine also prevents the augmentation of [3H]-ryanodine binding normally produced by caffeine and doxorubicin and exerts noncompetitive inhibition with regard to both releasing agents. Sphingosine significantly reduces in a dose-dependent manner [3H]-ryanodine binding to the high affinity site of the receptor and increases by several-fold the Kd for binding, which is consistent with a blocking action of sphingosine on the ryanodine receptor calcium channel. Sphingosine inhibits the extent of calcium-induced calcium release (CICR) and significantly shifts the threshold for CICR so that a higher level of trigger calcium is required to initiate CICR. The sphingosine inhibition of CICR is consistent with the near abolition of calcium dependent [3H]-ryanodine binding. HPLC analysis of cardiac sphingosine content indicates that sphingosine is present in the cardiac cell at moderately high levels (29.4 nmol/g wet wt for the entire cell and approximately 0.4 microM for the cytosol) which are sufficient to produce significant inhibition by sphingosine on calcium release and ryanodine binding. The data suggest that sphingosine acts on the cardiac ryanodine receptor by opposing the physiological stimulus (e.g. trigger calcium entering via the dihydropyridine receptor). We propose that sphingosine is produced by the T-tubule membranes and that sphingosine is released into the protected intracellular environment of the T-tubule/SR junction to negatively modulate calcium release. Consequently, it is possible that sphingosine is a physiologically relevant regulator of calcium levels in the heart.
肌肉细胞中的兴奋收缩(EC)偶联涉及钙通过肌浆网(SR)膜的钙释放通道(称为兰尼碱受体)的移动。我们最近发现,新型第二信使鞘氨醇可阻断经皮骨骼肌纤维和分离的骨骼肌SR膜的钙释放(Sabbadini等人,《生物化学杂志》267: 15475 - 15484, 1992)。在本报告中,我们证明,当由咖啡因、阿霉素或钙诱导释放时,鞘氨醇也抑制含有兰尼碱受体的分离犬心脏SR膜的钙释放。鞘氨醇还可防止通常由咖啡因和阿霉素产生的[3H] - 兰尼碱结合增加,并对两种释放剂均发挥非竞争性抑制作用。鞘氨醇以剂量依赖性方式显著降低[3H] - 兰尼碱与受体高亲和力位点的结合,并使结合的解离常数(Kd)增加数倍,这与鞘氨醇对兰尼碱受体钙通道的阻断作用一致。鞘氨醇抑制钙诱导的钙释放(CICR)程度,并显著改变CICR的阈值,因此需要更高水平的触发钙来启动CICR。鞘氨醇对CICR的抑制与钙依赖性[3H] - 兰尼碱结合几乎完全消除一致。心脏鞘氨醇含量的HPLC分析表明,鞘氨醇在心脏细胞中以中等高水平存在(整个细胞为29.4 nmol/g湿重,胞质溶胶约为0.4 microM),足以使鞘氨醇对钙释放和兰尼碱结合产生显著抑制。数据表明,鞘氨醇通过对抗生理刺激(例如通过二氢吡啶受体进入的触发钙)作用于心脏兰尼碱受体。我们提出鞘氨醇由横管膜产生,并且鞘氨醇释放到横管/SR连接的受保护细胞内环境中以负向调节钙释放。因此,鞘氨醇有可能是心脏中钙水平的生理相关调节剂。